Fulvestrant
SIGMA/I4409 - >98% (HPLC)
Synonym: (7α,17β)-7-[9-[(4,4,5,5,5-Pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol; Faslodex; ICI 182,780; ZD 182780; ZD 9238; ZM 182780
CAS Number: 129453-61-8
Empirical Formula (Hill Notation): C32H47F5O3S
Molecular Weight: 606.77
MDL Number: MFCD00903953
Linear Formula: C32H47F5O3S
Product Type: Chemical
| assay | >98% (HPLC) |
| form | powder |
| InChI | 1S/C32H47F5O3S/c1-30-17-1 |
| InChI key | VWUXBMIQPBEWFH-WCCTWKNTSA |
| originator | AstraZeneca |
| Quality Level | 100 ![]() |
| SMILES string | [H][C@]12CC[C@]3(C)[C@@H] |
| solubility | DMSO: >5 mg/mL |
| storage temp. | 2-8°C |
| Application: | Fulvestrant has been used: • as an antagonist of estrogen receptor (ERα and ER • as an antagonist of ER for the suppression of estrogen responsive element in human breast cancer MCF-7 cells • as anti-estrogen in breast cancer cell lines |
| Biochem/physiol Actions: | Fulvestrant (ICI 182,780) is a selective estrogen receptor down-regulator (SERD). Fulvestrant is a high affinity estrogen receptor antagonist. IC50 = 0.29 nM. Fulvestrant is the first "pure" antiestrogen with no agonistic activity both in vitro and in vivo. |
| Biochem/physiol Actions: | Fulvestrant is a 7α-alkylsulphinyl analog of 17β-oestradiol and is structurally different compared to other selective estrogen receptor (ER) modulators (SERMs). It reduces dimerization and nuclear localization of the estrogen receptor (ER). Fulvestrant lowers the level of ER protein in human breast cancer cells. Fulvestrant is preferred for the treatment of women at their menopause having hormone-sensitive advanced breast cancer. |
| Biochem/physiol Actions: | Fulvestrant is a selective estrogen receptor down-regulator (SERD); high affinity estrogen receptor antagonist. |
| Features and Benefits: | This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here . |
| Features and Benefits: | This compound was developed by AstraZeneca . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 25 mg in glass bottle |
| Hazard statements | H413 |
| Precautionary statements | P273 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Purity | >98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 51111800 |

